From 24 to The Last of Us – The Unforgettable Roles of Annie Wersching
Annie Wersching was a gifted actress whose talent, grace, and presence on screen captivated millions. Known for her compelling roles in popular TV series and films, she left an indelible mark on the entertainment industry. From portraying Renee Walker in
Who Was Annie Wersching?
Annie Wersching was born on March 28, 1977, in St. Louis, Missouri. From a young age, she was drawn to the performing arts. After studying musical theater at Millikin University, she launched a career that spanned over two decades. Whether on television, in movies, or in video game voice acting, Annie Wersching consistently delivered powerful and emotionally resonant performances.
Annie Wersching TV Shows: Memorable Performances on the Small Screen
Annie Wersching was best known for her work on television, where she played diverse and impactful roles. Her breakout role came in 2009 when she joined the cast of
Other notable Annie Wersching TV shows
The Vampire Diaries
Wersching played Lily Salvatore, the mysterious and powerful mother of Damon and Stefan Salvatore. Her performance brought new depth and drama to the popular CW series, introducing fans to a compelling villain with a complex backstory.
Timeless
In NBC’s Timeless, Wersching played the role of Emma Whitmore, a brilliant scientist who becomes a central figure in the show’s time-travel plot. Her performance added suspense and intrigue to the storyline.
Star Trek: Picard
One of her final television appearances was in Star Trek: Picard, where she portrayed the Borg Queen. This role allowed her to join the iconic Star Trek
Other appearances include guest roles in Supernatural, NCIS, Charmed, Bosch, and Runaways, cementing her reputation as a versatile and respected television actress.
Annie Wersching Movies: Impact on the Big Screen
While Annie Wersching was primarily known for her TV roles, she also appeared in a few notable films. Among the Annie Wersching movies
Bruce Almighty (2003)
Although a minor role, Wersching appeared in this hit Jim Carrey comedy early in her career, marking one of her first steps into mainstream Hollywood productions.
Below the Beltway (2010)
In this political drama, Wersching played opposite Tate Donovan in a story that explored life in Washington, D.C. This role gave her the opportunity to take on more dramatic material in a cinematic setting.
Wersching’s limited but meaningful film appearances revealed her ability to adapt across mediums and genres, solidifying her as an actress who could thrive in both TV and film.
Voice Acting: A Lasting Legacy in Gaming
One of Annie Wersching’s most beloved roles came in the form of voice acting. She provided the voice and motion capture for Tess in The Last of Us, one of the most acclaimed video games of all time. Her performance as Tess, a tough and resilient smuggler in a post-apocalyptic world, was both emotionally powerful and narratively critical.
The role endeared her to the gaming community and helped expand her fan base to a new generation of fans who appreciated her depth and realism in a video game character.
Personal Life and Legacy
Annie Wersching was married to actor and comedian Stephen Full. Together, they had three sons. Despite her busy career, she was known for being a devoted mother and wife, balancing her personal and professional life with grace.
Tragically, Annie Wersching passed away on January 29, 2023, at the age of 45 after a private battle with cancer. The news of her death shocked fans and colleagues alike, many of whom took to social media to share heartfelt tributes and memories.
Celebrating Annie Wersching’s Life and Career
Annie Wersching may be gone, but her legacy lives on through the unforgettable roles she played across television, film, and video games. Her performances in
Whether you’re a longtime fan or just discovering her work, revisiting Annie Wersching TV shows and Annie Wersching movies is a great way to appreciate the talent and impact of an actress who brought heart and soul to every role. She was a bright light in the entertainment world, and her contributions continue to inspire.
Dad with deadly brain cancer that kills in a year is cancer free after taking new drug
A breakthrough drug is fighting brain cancer head-on.
Glioblastoma is widely considered the deadliest form of brain cancer, killing over 10,000 Americans each year. There is no cure for the highly aggressive disease — many patients survive just nine months after diagnosis.
Ben Trotman was diagnosed with glioblastoma in October 2022 at 40.
Treatment focuses on managing symptoms and extending life via surgery to remove as much of the tumor as possible and radiation therapy and chemotherapy to destroy cancer cells.
Now, researchers from University College London Hospitals are recruiting glioblastoma patients for a trial of the immunotherapy drug ipilimumab. Sold under the brand name Yervoy, the monoclonal antibody stimulates the immune system to recognize and attack cancer cells.
Oncologists are optimistic since a UK father shows no signs of having a tumor after he took ipilimumab before his glioblastoma treatment.
Ben Trotman was diagnosed with glioblastoma in October 2022 at 40.
“The crucial element of this trial is that patients will have their immune system boosted by the drug before they have any other treatment, when they are fit and well enough to tolerate the immunotherapy,” said Dr. Paul Mulholland, the consultant medical oncologist leading the trial.
“We saw with Ben, the one patient recruited to the immunotherapy study, NeAT-GLIO, that he has had clear scans since having the treatment and the tumor hasn’t returned more than two and a half years later.”
Glioblastoma is widely considered the deadliest form of brain cancer, killing over 10,000 Americans each year.
Trotman met with Mulholland, who enrolled him in a clinical trial for ipilimumab. He was the first patient in the world — and the only person in the trial — to take the drug before glioblastoma treatment.
“Getting this diagnosis was the most traumatic experience,” said Trotman’s wife, Emily.
“We were grappling with the fact that Ben had gone from being apparently perfectly healthy to having months to live.”
After taking the drug, Ben underwent radiotherapy and chemotherapy.
Two years and eight months later, his scans are clear.
“It is very unusual to have a clear scan with glioblastoma, especially when he didn’t have the follow-up surgery that had been planned to remove all of the tumor that was initially visible on scans,” Mulholland said.
Ben and Emily Trotman wed in 2023, after he began his immunotherapy treatment.
“We hope that the immunotherapy and follow-up treatment Ben has had will hold his tumor at bay,” he added, “and it has so far, which we are delighted to see.”
In January 2023, months after his diagnosis, Ben married Emily. The couple welcomed a daughter, Mabel, earlier this year.
They enjoy taking her for walks along with their rescue dog, Jerry.
“We are trying to live as normal a life as possible,” Emily said.
“We are in a unique position of which there is no precedent and which comes with a great deal of uncertainty,” she continued. “We want to live each day as if it were our last, but we also want to plan for the future, which we hope to have.”
Researchers plan to recruit 16 glioblastoma patients like Ben over 18 months.
After taking ipilimumab, the trial participants will undergo radiotherapy and chemotherapy and perhaps surgery depending on the extent of their disease.
Dr. Paul Mulholland and Dame Siobhain McDonagh, who raised funds for the new clinical trial of ipilimumab.
The trial is being funded by Dame Siobhain McDonagh, a member of the British Parliament, whose sister died of glioblastoma in 2023.
“My beloved sister Margaret was appalled to discover that there had been no advances in brain cancer treatment for decades when she was diagnosed with glioblastoma,” McDonagh said. “Changing this was Margaret’s final campaign and one that I have continued in her memory.”
Treatment will take place at the NIHR UCLH’s Clinical Research Facility at the National Hospital for Neurology and Neurosurgery.
“I am delighted that this new trial, with the same immunotherapy drug I received, is going ahead and others will have the opportunity to take part,” Ben said. “It will give people newly diagnosed with glioblastoma some hope.”
